Document ID: FDA-2014-N-0189-4670
Agency: fda
Document Type: Supporting & Related Material
Title: 
Posted Date: 2014-06-15T04:00Z

Comment Info: =================

General Comment:Dear Mr. Zeller:

My name is Kim Peyton and I am writing as an individual consumer to request an extension of the comment period for the Food and Drug Administration's ("FDA") Proposed Rule Deeming Tobacco Products to be Subject to the Federal Food, Drug, and Cosmetic Act, as amended by the Family Smoking and Prevention and Tobacco Control Act (the "Proposed Rule") published at 79 Fed. Reg. 23,142 and Federal Register No. 2014-09491. On behalf of myself, I am requesting that the comment period for the Proposed Rule be extended by the FDA for an additional 105 days, from its current 75-day period, to 180 days.

The Proposed Rule raises a number of significant issues and questions that are important and relevant to me, as a consumer of products that are proposed for regulation under the Proposed Rule. I have been reading and taking notes but the Proposed Rule asks about a hundred different questions I might want to respond to. I want to provide my thoughts and comments on many of these issues, but my time to devote to researching is only an hour or two each day. I have been reading several pages a day and I realize that I may not get to respond in an informed way at this rate. It is very important that to me to be able to not only comment but to truly understand what I am commenting on and that my answers be well researched and well thought out.  I know that the FDA took many years to even come up with the Proposed Rule, so I do not think it is at all unreasonable to allow the public more time to understand it and to comment on it. This is our only chance to voice our opinion and to provide feedback. 

 My quality of life has greatly improved since I started using e-cigarettes as an alternative to combustible cigarettes and I firmly believe that they saved my life. I want to provide you with my story. I also want to respond to your questions with science and evidence so that you can take my comment into account. I realize that the FDA has the authority under 21 CFR 10.40 to extend this time frame and that the FDA has exercised this authority on numerous occasions in the past. I would therefore ask that you do so here, so that all stakeholders have the opportunity to provide their comments on this proposed regulation. Thank you, Kim Peyton